ECOG-ACRIN Cancer Research Group

Chemotherapy before surgery helps patients with nose and sinus #cancer avoid debilitating eye and bone removal. Striking #clinicaltrial results at #ESMO24. #CancerSurgery @DrNabilSaba @WinshipAtEmory Barbara Burtness @YaleCancer @NCI_CTEP https://lnkd.in/efHGnCW7

Striking #clinicaltrial results to be presented at #ESMO24 https://lnkd.in/efHGnCW7 #CancerSurgery #Science #News #Media #Medicine #Europe #patientcare #healthcare #MedComms #Breaking #Oncology #Cancer @DrNabilSaba @WinshipAtEmory Barbara Burtness @YaleCancer @NCI_CTEP

There is still time to submit a research abstract for early-career investigators interested in presenting your research as part of the upcoming Fall 2024 Group Meeting. The submission deadline is tomorrow, Thursday, September 12 at 11:59 PM (Eastern Time). More here: https://lnkd.in/eXJSAGFM

There is one week left to submit an abstract for the 2024 Young Investigator Symposium! 🩺 The Symposium is an opportunity for early-career researchers to share their work, connect w/ experienced investigators, & learn about potential research opportunities. https://lnkd.in/eXJSAGFM

Patients have a lot on their plates. Among the priorities of the Biden Administration’s ambitious Cancer Moonshot initiative is to increase access to individuals in hospitals and cancer centers to help guide patients through the healthcare system. Read more about these services, which have been shown to improve the patient experience and treatment outcomes by helping patients and caregivers manage the many challenges of a cancer diagnosis. Navigation can also help to advance another national goal: including more patients in clinical trials. #patientcare #patientnavigation #patientnavigator #cancermoonshot #clinicaltrials #medicalresearch https://lnkd.in/eN5vPDNc

ICYMI: Submit an Abstract for the 2024 Young Investigator Symposium! 🩺 The Symposium is an opportunity for early-career #researchers to share their work, connect with experienced #investigators, and learn about potential research #opportunities. More here: https://lnkd.in/eXJSAGFM

In case you missed it, the remarkable results of study E1910 were published (NEJM Group) late last month. Presented by Mark Litzow, MD (Mayo Clinic) at the American Society of Hematology annual meeting in 2023, the results led to the FDA approval of blinatumomab for adults with newly diagnosed BCR-ABL1-negative B-lineage acute lymphoblastic leukemia. Eligible patients had achieved complete remission with standard therapy and were negative for minimal residual disease (MRD). At 3 years of follow-up, 85% of the patients who went on to receive additional standard consolidation chemotherapy plus experimental blinatumomab were alive, compared to 68% of those who received chemotherapy only. The survival curves suggest a durable effect in the patients who received blinatumomab. We recognize and thank all of the adult cooperative groups--Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, NRG ONCOLOGY, and SWOG Cancer Research Network--in the @National Cancer Institute's National Clinical Trial Network, for contributing to this practice-changing advance. Blinatumomab is a BiTE, a bispecific T-cell engager (Amgen), that approximates T-cells to CD28-expressing leukemia cells. BiTEs have striking activity in other hematological malignancies, including myeloma, and show great therapeutic promise. #leukemia #FDAapproval #MedicalResearch https://lnkd.in/eFkJTmSQ

Please read this trial update from Dr. Nataliya Uboha, lead investigator for EA2183, which is currently enrolling patients with esophageal and stomach cancer with limited spread. Recent changes to the trial broaden eligibility for patients and permit more therapeutic options once enrolled. This randomized phase 3 trial explores the addition of radiotherapy to the usual treatment (chemotherapy). https://lnkd.in/g83msaAH

ℹ️ Exciting news in medical research! Real-world data (RWD) will soon be collected on patients with non-small cell lung cancer receiving osimertinib, with or without chemotherapy, in routine clinical practice. This innovative study aims to enhance our understanding of the safety and effectiveness of osimertinib, a newly approved therapy that physicians routinely prescribe. The data collected by PrECOG Cancer Research Group and ECOG-ACRIN Cancer Research Group in this registry will have the potential to provide valuable insights into side effects, patient benefits, survival rates, patient-reported outcomes, and outcomes based on various demographic variables. Stay tuned for updates on this groundbreaking research! 🌟🔬 #MedicalResearch #Osimertinib #FDA https://lnkd.in/e8vuP63w

Submit an Abstract for the 2024 Young Investigator Symposium by Thursday, 9/12! We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2024 Group Meeting. More info: https://lnkd.in/eXJSAGFM